FluoroPharma Medical is focused on discovering and developing patented Positron Emission Tomography (PET) imaging products designed to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing four different PET imaging agents, which differ from imaging tools such as MRI, CT, and Ultrasound in that they candetect and asses pathology before serious signs of disease are evident.

The company’s CardioPET, for the detection of coronary artery disease, uses a radio-labeled analog to the natural fatty acids utilized as an energy source by the heart, allowing for the visualization of the anatomic location and state of the muscle to detect problems in advance of symptoms that would lead to a stress test. This agent is slated to enter phase IIb clinical trials by year end.

BFPET is also for the detection of coronary artery disease. BFPETis designed to enter the myocardial cells in direct proportion to blood flow and cell membrane potential, two of the most important physiological indicators contributing to adequate blood supply to the heart. BFPET has been designed to differentiate among those cells of the myocardium that may be ischemic, infarcted and those that are healthy.Phase II clinical trial results are expected by year end.

FluoroPharma’s third agent for coronary artery diseases is VasoPET. This imaging agent allows clinicians the ability to visualize potential areas that may cause embolisms and thrombosis. VasoPET is designed for patients that have already had a heart attack or stroke with the risk of a potentially fatal recurrence. The agent is on track for phase Ib clinical trial by year end.

Lastly, the company’s AZPET imaging agent addresses Alzheimer’s disease by attaching to the amyloid deposits (plaque) in the brain and makes them visible on a PET scan, thus allowing the early detection of the disease.

For more information visit www.fluoropharma.com